Vaccine Science & Therapeutics
Beyond the Booster: How Upstart Biotechs Are Engineering the Next Era of mRNA Medicine
The mRNA revolution ignited by COVID-19 vaccines is far from finished — it is, in many ways, just beginning. A new generation of biotech companies and pharmaceutical giants are engineering more stable, more versatile, and deeply personalized mRNA platforms that extend well beyond infectious disease. The stakes are enormous, the science is accelerating, and the competitive landscape has never been more consequential.